Patent Assignment
Reel/Frame 030679/0116
Security Agreement
Recorded: 2013-06-25
Pages: 32
Assignor
KADMON CORPORATION LLC
Executed: 2013-06-17
Assignee
MACQUARIE US TRADING LLC
225 WEST WASHINGTON STREET, 21ST FLOOR, CHICAGO, ILLINOIS, 60606
Covered Properties
(57)
Methods of Inhibiting Receptor Tyrosine Kinases with an Extracellular Antagonist and an Intracellular Antagonist
PCT:
PCT/US2004/018451 ↗
Inhibitors of Mtor Kinase as Anti-Viral Agents
PCT:
PCT/US2010/043101 ↗
Receptor-Type Kinase Modulator and Methods of Treating Polycystic Kidney Disease
PCT:
PCT/US2011/049077 ↗
Anti-Viral Combination Therapy
PCT:
PCT/US2012/032567 ↗
Dengue Virus and Yellow Fever Virus Therapy
PCT:
PCT/US2012/052344 ↗
Methods for Treatment of Breast Cancer Nonresponsive to Trastuzumab
PCT:
PCT/US2012/071883 ↗
Farnesyl Derivatives and Pharmaceutical Compositions Containing Them
Patent:
5,705,528 →
Application:
08/338,764 →
Cytokine Related Treatments of Disease
Patent:
6,423,695 →
Application:
09/467,443 →
Nucleoside Compounds and Uses Thereof
Patent:
6,495,677 →
Application:
09/594,410 →
Methods for Treating Diseases with Tirazole and Pyrrolo-Pyrimidine Ribofuranosyl Nucleosides
Patent:
6,455,508 →
Application:
09/595,365 →
Non-Malignant Disease Treatment with Ras Antagonists
Patent:
6,462,086 →
Application:
09/597,332 →
Tirazole Nucleoside Analogs and Methods for Using Same
Herbal Composition PHY906 and Its Use in Chemotheraphy
Nucleoside Analogs with Carboxamidine Modified Monocyclic Base
Nucleoside Compounds and Uses Thereof
Treatment of Post-Angioplasty Restenosis and Atherosclerosis with Ras Antagonists
Receptor-Type Kinase Modulators and Methods of Use
Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
Application:
10/560,209 →
Publication:
US 2007/0036795
Use of Ribofuranose Derivatives Against Inflammatory Bowel Diseases
Herbal Composition PHY906 and Its Use in Chemotherapy
Inhibitors of Microsomal Triglyceride Transfer Protein and Apo-B Secretion
Antibodies That Bind Mmp-14
Methods and Compositions for Oral Delivery of Fts
Pharmacokinetically Improved Compounds
Treatment of Viral Infections by Modulation of Host Cell Metabolic Pathways
Compositions and Methods for Treating Osteolytic Disorders Comprising Mmp-14 Binding Proteins
Evaluating Mmp Expression in Patient Stratification and Other Therapeutic, Diagnostic and Prognostic Methods for Cancer
Methods of Inhibiting Receptor Tyrosine Kinases with an Extracellular Antagonist and an Intracellular Antagonist
Application:
12/361,350 →
Publication:
US 2009/0232805
Receptor-Type Kinase Modulators and Methods of Use
Treatment of Lung Cancer
Herbal Composition PHY906 and Its Use in Chemotherapy
Alkoxyalkyl S-Prenylthiosalicylates for Treatment of Cancer
Metalloproteinase Binding Proteins
Use of the Combination of PHY906 and a Tyrosine Kinase Inhibitor as a Cancer Treatment Regimen
Methods of Treating Hepatitis C Virus Infection
Application:
13/078,344 →
Publication:
US 2011/0243894
Combination Treatments Comprising Protease Binding Proteins for Inflammatory Disorders
Application:
13/124,046 →
Publication:
US 2011/0262396
Rho Kinase Inhibitors
Application:
13/255,879 →
Publication:
US 2012/0202793
Methods and Compositions for Oral Delivery of Fts
Application:
13/326,598 →
Publication:
US 2012/0082722
Method for Treating Breast Cancer Using Antibody Binding to Mmp-14
Compositions and Methods for Treating Osteolytic Disorders Comprising Mmp-14 Binding Proteins
Inhibitors of Mtor Kinase as Anti-Viral Agents
Application:
13/386,547 →
Publication:
US 2012/0190676
Inhibition of Glycerol-3-Phosphate Acyltransferase (GPAT) and Associated Enzymes for Treatment of Viral Infections
Treatment of Viral Infections by Modulation of Host Cell Metabolic Pathways
Evaluating Mmp Expression in Patient Stratification and Other Therapeutic, Diagnostic and Prognostic Methods for Cancer
Application:
13/454,534 →
Publication:
US 2013/0244890
Treatment of Multiple Sclerosis
Application:
13/521,637 →
Publication:
US 2013/0035390
Treatment of Lung Cancer
Application:
13/559,737 →
Publication:
US 2012/0294957
Herbal Composition PHY906 and Its Use in Chemotherapy
Application:
13/648,597 →
Publication:
US 2013/0101688
Pharmacokinetically Improved Compounds
Pharmacokinetically Improved Compounds
Methods of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
Application:
60/477,796 →
Inhibitors of Long and Very Long Chain Fatty Acid Metabolism as Broad Spectrum Anti-Virals
Application:
61/305,862 →
Anti-Viral Combination Therapy
Application:
61/472,608 →
Combination Therapy Comprising an Mmp-14 Binding Protein
Application:
61/549,873 →
Methods for Treatment of Breast Cancer Nonresponsive to Trastuzumab
Application:
61/580,543 →
Rho Kinase Inhibitors
Application:
61/710,373 →
Human Anti-Vegfr-2/Kdr Antibodies
Application:
61/710,420 →
Treatment of Ocular Disease
Application:
61/710,467 →
Related Assignments
(23)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Agreement
Jun 25, 2013
From: KADMON CORPORATION LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030679/0212 →
Notice of Succession of Agency
Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
Security Interest
Aug 31, 2015
From: KADMON CORPORATION, LLC
To: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
Reel/Frame 036515/0084 →
Release of Security Interest
Sep 1, 2015
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 036518/0862 →
Security Interest
Sep 8, 2015
From: KADMON CORPORATION, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 036573/0001 →
Nunc Pro Tunc Assignment
Jul 15, 2016
From: CONCORDIA PHARMACEUTICALS, INC.
To: KADMON CORPORATION, LLC
Reel/Frame 039166/0591 →
Assignment of Assignor's Interest
Jul 22, 2016
From: KADMON CORPORATION, LLC
To: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Reel/Frame 039225/0943 →
Corrective Assignment to Correct the Assignor's Name Previously Recorded at Reel: 039166 Frame: 0591. Assignor(S) Hereby Confirms the Assignment.
Aug 16, 2016
From: CONCORDIA PHARMACEUTICALS, LLC
To: KADMON CORPORATION, LLC
Reel/Frame 040314/0329 →
Security Interest
Jul 19, 2017
From: VALEANT PHARMACEUTICALS INTERNATIONAL
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043045/0913 →
Security Interest
Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
Security Interest
Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
Security Interest
Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
Intellectual Property Security Agreement
Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
Termination of Patent and Trademark Security Agreement
Nov 25, 2019
From: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
To: KADMON CORPORATION, LLC
Reel/Frame 051106/0677 →
Assignment of Assignor's Interest
May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →
Security Interest
Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
Release of Security Interest
Oct 21, 2021
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057886/0192 →
Release of Security Interest
Oct 29, 2021
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057973/0751 →
Release of Security Interest
Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.
Reel/Frame 070778/0199 →
Entity Conversion
Sep 17, 2025
From: SURFACE LOGIX, INC.
To: SURFACE LOGIX LLC
Reel/Frame 072915/0828 →
Release of Security Interest
Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 073637/0222 →
Release of Security Interest
Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.
Reel/Frame 073637/0126 →
Release of Security Interest
Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
Reel/Frame 073637/0001 →